https://rijournals.com/scientific-and-experimental-sciences/

RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 4(3):27-30, 2024

©RIJSES Publications ONLINE ISSN: 1115-618X

PRINT ISSN: 1597-2917

https://doi.org/10.59298/RIJSES/2024/432730

Nanomedicine: Harnessing Nanotechnology for Disease Treatment

Irakoze Mukamana S.

School of Applied Health Sciences Kampala International University Uganda

ABSTRACT

Nanomedicine integrates nanotechnology with medicine to address complex challenges in disease diagnosis, treatment, and prevention. By engineering nanomaterials, nanomedicine enables targeted drug delivery, enhances diagnostic imaging, and facilitates precision therapies with reduced systemic side effects. Applications in cancer treatment, cardiovascular diseases, and neurodegenerative disorders have demonstrated significant advancements, particularly in improving therapeutic efficacy and personalization. Despite its transformative potential, the field faces challenges, including biocompatibility, regulatory concerns, and public perception. Future innovations, such as nanorobotics and advanced smart materials, combined with multidisciplinary collaboration, are poised to unlock new horizons in nanomedicine, revolutionizing healthcare for personalized and preventive medicine.

Keywords: Nanotechnology, Nanomedicine, Targeted Drug Delivery, Cancer Treatment, Diagnostics.

INTRODUCTION

Nanomedicine refers to the application of nanotechnology in medicine. It has the potential to ultraprecisely treat disease at the molecular level. This could revolutionize the delivery of systemic drugs, known to have a wealth of off-target side effects on the body, and to lead to the development of new, highly sensitive diagnostic drugs, as well as therapies that are tightly targeted to disease tissues. Thus, nanomedicine has the potential to impact numerous unmet medical needs in diverse disease areas including cardiovascular, neurodegenerative, and autoimmune diseases, as well as cancer [1, 2]. At its most basic, nanomedicine seeks to enhance the delivery of drugs to specific cells and tissues within the body in order to improve therapeutic efficacy. Imaging agents can be similarly targeted for enhanced diagnostic sensitivities. This could also provide a therapeutic benefit in the context of therapies such as image-guided surgeries or personalized medicine, where a tailored therapy is used based on imaging data acquired from the patient. It can also identify non-responders at the early stage of treatment. There are barriers to the translation and commercialization of nanomedicines, their diagnostics, and devices, which require more focused efforts in terms of regulatory processes and nanosafety, as well as patient access to these products. There is increasing acceptance of the concept of nanomedicine, which combines the enabling power of nanotechnology with the life sciences and medical practice, across industry, academia, and regulatory agencies. It is well placed to contribute to delivering better diagnostics and more effective therapies with fewer side effects for the modern era of personalized medicine. There exists a good portfolio of examples and current best practices which it is now vital to build upon. Finally, there is a growing readiness for a policy-driven vision and strategic landscape planning of the subject in the UK in the future [3, 4]. Nanomaterials are a class of materials defined by their nanoscale dimensions and possess unique properties owing to their high surface area, size, and reactivity. The field of nanotechnology capitalizes on the engineering of materials at the nanoscale for a wide range of applications, from electronics to medicine. The field of nanomedicine represents an area of research that harnesses these properties for new methods in treatment, diagnosis, and drug delivery. A wide range of materials can be engineered as nanoparticles, nanowires, nanotubes, nanoscaffolds, nanodisks, nanoellipsoids, nanorods, nanoshells, nanocapsules, nanospheres, and even nanorobots. These components can, in turn, be engineered to interact with cellular, subcellular, and intracellular targets. For medical applications, one of the major advantages of nanotechnology is the relative ease with which nanoparticles can be surface modified to enhance their biological and biocompatible properties [5, 6]. Nanostructures can interact at the large cellular scale, down to the molecular scale, and the intrinsic properties and surrounding physical parameters dictate their interaction and internalization into a cell. A wide range of methods can be used to generate nanoscale materials, although not all of these are compatible with biomedicinal applications. Methods such as sol-gel, physical vapor deposition, chemical vapor deposition, magnetron sputtering, and molecular beam epitaxy are used in semiconductor research and fabrication for the creation of ultra-high precision thin films and semiconductors; soft lithography techniques can also be used to control structures on the macromolecular nanoscale. Fabrication techniques are chosen based on the desired material type, structure, size, scale of fabrication, throughput time, and instrument cost. Another major consideration in the development of materials for nanomedical applications, along with possible cost, is biocompatibility, that is, the lack of treatment-related side effects from the application of these materials in vivo [7, 8].

Nanoparticles For Drug Delivery

Abbreviated abstract: Drug delivery based on nanoparticles involves water-insoluble drugs such as certain types of cytotoxics in cancer treatment. For these drugs, loaded into nanoparticles, good water solubility can be achieved, which is critical for their parenteral administration. Parenteral liposomal preparations for cytostatics have been in the clinic for over a decade. Nanoparticles, initially used for non-lipophilic drugs, have also been successfully employed to deliver macromolecular drugs from the cell genomics area. This is interpreted as a consequence of nanoparticle-facilitated passive tissue barriers. Passive pathways are diffusive and thus valid for all of the different strategies. The most successful nanoparticle technologies employ lipid nanoemulsions as drug carriers [9, 10]. Many advantages are provided for the development of nanoparticle-based drug delivery systems. Important features include good bioavailability with other drug delivery systems, stability in biological environments, low organ distribution, low clearance from the body, good production potential, and above all, the potential to provide tissue-specific, e.g., tumor-specific drug targeting. The active use of nanoparticles to improve penetration and diffusion of drugs into cells emerged only recently, however. This is a consequence of a fine understanding of the concept of nanoparticle-assisted cytosis, of which c-PAP is the principal element. The following account will address nanoparticle design and use for intracellular nanomedicine. Potential examples should illustrate the wide range but also the feasibility of nanoparticle-based drug delivery strategies. In addition, suitable options in the case of nanomedicinal strategies are discussed through varying degrees of personalization of patients [11, 12].

Applications of Nanomedicine in Cancer Treatment

Nanotechnology offers innovative solutions in the fields of molecular imaging, gene therapy, and drug delivery. Nanoparticles are diverse and have a variety of applications in tissue and organ targets. They are multifunctional. Drug targeting of tumors is one of the main applications of nanomedicine in cancer. Nanoparticle-based therapies carry a lot of potential in cancer treatment. Researchers continue to use various nanoparticles, including liposomes, polymers, and albumin for drugs and biologicals. Various targeting strategies are being developed for nanoparticles, while the EPR effect is still the driving force in clinical trials. Nanoparticles can overcome the biological barriers of human tumors, including the interstitial fluid pressure that inhibits drug and immune distribution. Imaging of nanoparticles in molecular imaging has become an important part of cancer detection and early diagnosis because most of the existing imaging techniques cannot detect them when they are only a few millimeters or at the molecular level. Nanotechnology is widely used in various fields of medicine to improve health care and well-being, including imaging, diagnosis, therapy, and drug development. Liposomal nanomedicine has been used in cancer treatment. It has been developed into a variety of drugs with prolonged blood circulation and target receptor proteins that induce apoptotic methods such as liposomal nucleic acids and liposomal RNA interference. Nanotechnology helps to increase the time of drug circulation in the blood and reduce cell resistance based on the replacement of small chemotherapeutics. Until now, a variety of nanomanufacturing formulations have been approved for clinical trials and commercialization. Nanoparticle technology for drug delivery and release has the potential to revolutionize anti-cancer drug chemotherapy and radiotherapy [13, 14].

Challenges and Future Directions in Nanomedicine

Given that the field of nanomedicine is in its infancy, it is still faced with an array of surmountable challenges. Considerable efforts are underway to address key barriers to the broad application of nanotechnology and nanomedicine in various aspects of human health and disease. Issues can vary from a need to develop clear guidelines and protocols in the research and development of nanomedicine products to address regulatory barriers. Some concerns are still causing worry, such as the unforeseen long-term chronic effects, which regulatory bodies might consider a serious concern [15, 16]. One of the major concerns remains the safety of nanoparticles and their potential toxicity. A body has been developed to address some of the major public health issues of nanotechnology, including the safety and ethical aspects of nanomedicine. The task force has identified the need for a systematic investigation into nanoparticle/cell association for an accurate determination of long-term nanoparticle-cell interactions. Moreover, a clear alliance between the regulatory bodies, the public, and applied scientists seems fundamental to ensure that the development of nanomedicine addresses the ethical questions raised and promotes public consensus. All of these factors must be taken into account to develop the nanomedicine field to its full potential. A strategic partnership must be developed both within and beyond the scientific community, and this must incorporate scientists in early multidisciplinary research, in close collaboration with clinicians and regulatory bodies, to ensure that research can proceed quickly and safely [17, 18]. The broader challenges to medicine that involve cutting-edge technologies include regulatory boundaries, interface hurdles between medical disciplines, and investors' apathy and abnormalities associated with some treatments. The successful deployment of nanotechnology will lead the body to a crisis of epistemological novelty. The growing interest in nanomedicine and nanorobotics is likely due to advances in nanoscale materials, with trends changing every few years. In addition to smart nanomaterials, other future innovations are also emerging: these include the use of nanorobotics in medical technology. Independent problem-solving without human intervention refers to the roles of nanorobots in nanomedicine. This will most likely be an important development in the case of nanostructure therapy and diagnosis. The use of self-propelled micro and nanodevices in a biological environment is a primary concern. In the future, new physical principles and new materials will have to be employed to design high-performance nanostructures, especially for biomedical applications. It is critical to continue research in these areas. Public collaboration and guidance will also be needed to transform these ongoing investigations into sustained public solutions. Public education is important for the fundamental understanding and acceptance of results from experiments on the long-term and widespread use of nanoparticles in biological systems. A national and international effort is needed to make nanotechnology a real gateway to healthcare, rather than just a technology that supports the economy [19, 20].

CONCLUSION

Nanomedicine represents a transformative frontier in healthcare, offering unparalleled precision and efficacy in disease treatment and management. The integration of nanotechnology into medical practice has demonstrated significant advancements, particularly in cancer therapy and personalized medicine. By addressing key challenges, such as biocompatibility and regulatory barriers, and fostering interdisciplinary collaboration, the potential of nanomedicine can be fully realized. Future directions emphasize the need for innovative materials, such as self-propelled nanorobots, and enhanced public understanding to ensure widespread acceptance and ethical deployment. With continued research and strategic planning, nanomedicine promises to redefine modern healthcare, enhancing patient outcomes and global health standards.

REFERENCES

1. Germain M, Caputo F, Metcalfe S, Tosi G, Spring K, Åslund AK, Pottier A, Schiffelers R, Ceccaldi A, Schmid R. Delivering the power of nanomedicine to patients today. Journal of Controlled Release. 2020 Oct 10;326:164-71. sciencedirect.com
2. Sato Y, Nakamura T, Yamada Y, Harashima H. The nanomedicine rush: new strategies for unmet medical needs based on innovative nano DDS. Journal of controlled release. 2021 Feb 10;330:305-16. [HTML]
3. Garbayo E, Pascual-Gil S, Rodríguez-Nogales C, Saludas L, Estella-Hermoso de Mendoza A, Blanco-Prieto MJ. Nanomedicine and drug delivery systems in cancer and regenerative medicine. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2020 Sep;12(5):e1637. [HTML]

4. Rommasi F, Esfandiari N. Liposomal nanomedicine: applications for drug delivery in cancer therapy. Nanoscale Research Letters. 2021 May 25;16(1):95.
5. Gholami M, Morris K, Torres A, Kamal TT, Jahromi BR, Haridas A, Kateb B. Applications and Recent Advances of Nanotechnology and Nanomedicine in the Diagnosis and Therapy of Stroke. The Textbook of Nanoneuroscience and Nanoneurosurgery. 2024 Nov 14:275-302. [HTML]
6. Ibrahim HK. From Nanotech to AI: The Cutting-Edge Technologies Shaping the Future of Medicine. African Journal of Advanced Pure and Applied Sciences (AJAPAS). 2024 May 30:410-27. aaasjournals.com
7. Oroojalian F, Beygi M, Baradaran B, Mokhtarzadeh A, Shahbazi MA. Immune cell Membrane-Coated biomimetic nanoparticles for targeted cancer therapy. Small. 2021 Mar;17(12):2006484. helsinki.fi
8. Amina SJ, Guo B. A review on the synthesis and functionalization of gold nanoparticles as a drug delivery vehicle. International journal of nanomedicine. 2020 Dec 7:9823-57.
9. Li Y, Ye Z, Yang H, Xu Q. Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs. Acta Pharmaceutica Sinica B. 2022 Jun 1;12(6):2624-39.
10. Zhang Y, Huang C, Xiong R. Advanced materials for intracellular delivery of plant cells: Strategies, mechanisms and applications. Materials Science and Engineering: R: Reports. 2024 Sep 1;160:100821.
11. de la Torre P, Pérez-Lorenzo MJ, Alcázar-Garrido Á, Flores AI. Cell-based nanoparticles delivery systems for targeted cancer therapy: lessons from anti-angiogenesis treatments. Molecules. 2020 Feb 7;25(3):715. mdpi.com
12. De Rubis G, Paudel KR, Corrie L, Mehndiratta S, Patel VK, Kumbhar PS, Manjappa AS, Disouza J, Patravale V, Gupta G, Manandhar B. Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease. Naunyn-Schmiedeberg's archives of pharmacology. 2024 May;397(5):2793-833. [HTML]
13. Mirza Z, Karim S. Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges. InSeminars in cancer biology 2021 Feb 1 (Vol. 69, pp. 226-237). Academic Press.
14. Gavas S, Quazi S, Karpiński TM. Nanoparticles for cancer therapy: current progress and challenges. Nanoscale research letters. 2021 Dec 5;16(1):173.
15. Xu X, Xu L, Wen C, Xia J, Zhang Y, Liang Y. Programming assembly of biomimetic exosomes: an emerging theranostic nanomedicine platform. Materials Today Bio. 2023 Aug 11:100760.
16. Bibri SE. The metaverse as a virtual model of platform urbanism: its converging AIoT, XReality, neurotech, and nanobiotech and their applications, challenges, and risks. Smart Cities. 2023 May 11;6(3):1345-84.
17. Samuel MS, Ravikumar M, John J A, Selvarajan E, Patel H, Chander PS, Soundarya J, Vuppala S, Balaji R, Chandrasekar N. A review on green synthesis of nanoparticles and their diverse biomedical and environmental applications. Catalysts. 2022 Apr 20;12(5):459. mdpi.com
18. Abbasi R, Shineh G, Mobaraki M, Doughty S, Tayebi L. Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review. Journal of Nanoparticle Research. 2023 Mar;25(3):43. springer.com
19. Wang J, Dong Y, Ma P, Wang Y, Zhang F, Cai B, Chen P, Liu BF. Intelligent Micro-/Nanorobots for Cancer Theragnostic. Advanced Materials. 2022 Dec;34(52):2201051. [HTML]
20. Feng Y, An M, Liu Y, Sarwar MT, Yang H. Advances in chemically powered micro/nanorobots for biological applications: a review. Advanced Functional Materials. 2023 Jan;33(1):2209883. google.com

CITE AS: Irakoze Mukamana S. (2024). Nanomedicine: Harnessing Nanotechnology for Disease Treatment. RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 4(3):27-30.
https://doi.org/10.59298/RIJSES/2024/432730